U.S. Vascular Graft Market Size, Share & Forecast 2026–2032

ID: MR-11938 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Vascular Graft Market
  • ✓Market Size 2024: USD 1.12 billion
  • ✓Market Size 2032: USD 1.78 billion
  • ✓CAGR: 6.0%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Medicare Bundling Shapes Graft Choice: Under MS-DRG reimbursement, hospitals absorb a fixed payment per aortic repair, pushing procurement toward lower-cost ePTFE and Dacron grafts rather than premium systems. Value-analysis committees at large health systems now run tender processes that favor Terumo Aortic and Medtronic through price concessions.
FINDING 02
Dialysis Access Outpaces Aortic: Most analysts treat aortic repair as the growth engine, yet dialysis access grafts are gaining volume faster. Fistula-first policy and CMS Kidney Care Choices incentives push nephrologists toward ePTFE access grafts from Gore and Bard Peripheral Vascular, sustaining demand.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock Supply Before Tariffs: Procurement directors at U.S. hospital systems should renegotiate ePTFE and Dacron graft contracts with Gore or Terumo Aortic before the third quarter of 2026, fixing prices ahead of any Section 232 medical device tariffs.

Vascular Grafts in the United States: Market Overview

The U.S. vascular graft market was valued at USD 1.12 billion in 2024 and is forecast to reach USD 1.78 billion by 2032, accounting for roughly 40 percent of global demand. Most synthetic aortic and peripheral grafts are regulated by the Food and Drug Administration as Class III implantable devices under the Federal Food, Drug, and Cosmetic Act, requiring premarket approval before commercial sale. This regulatory gate has concentrated supply among a small number of manufacturers able to fund multi-year clinical programs.

Private industry leads product design and manufacturing. W. L. Gore and Associates pioneered expanded PTFE grafts, while Terumo Aortic and Artivion compete in woven polyester and tissue-based aortic products. Government leads demand. Centers for Medicare and Medicaid Services (CMS) payment rules under MS-DRG and the Outpatient Prospective Payment System determine which graft types hospitals can afford, and the Department of Veterans Affairs buys through national contracts managed by its National Acquisition Center.

Policy-Driven Growth in Vascular Grafts in the United States

Three mechanisms drive demand. First, the CMS Inpatient Prospective Payment System grants new technology add-on payments (NTAP) of up to 65 percent of device cost for qualifying grafts under annual IPPS final rules, reducing financial risk for hospitals adopting endovascular and hybrid designs. Second, the CMS ESRD Prospective Payment System and the Kidney Care Choices model reward dialysis providers for maintaining hemodialysis patients, and access grafts serve patients whose veins cannot sustain a fistula.

Third, the Medical Device User Fee Amendments under MDUFA V, covering fiscal years 2023 through 2027, commit FDA to decide 90 percent of original premarket approval applications within 180 review days. Faster clearance shortens the interval between trial completion and commercial launch, bringing new graft designs to market sooner. Each mechanism converts policy into volume: payment rules make procedures financially viable, while user fee timelines accelerate product supply.

Regulatory Barriers and Compliance Costs

The most costly barrier is premarket approval administered by FDA's Center for Devices and Radiological Health under 21 CFR Part 814. Manufacturers must submit pivotal trial data, and analyst estimates place total development cost for a new implantable graft above USD 10 million, with reviews commonly extending beyond 12 months. From February 2, 2026, the Quality Management System Regulation replaces the Quality System Regulation at 21 CFR Part 820, aligning U.S. requirements with ISO 13485:2016 and requiring revised design control and supplier audit systems.

Trade measures create the second barrier. The Commerce Department's Bureau of Industry and Security opened a Section 232 investigation into imported medical devices in September 2025, and any resulting tariffs would raise landed costs for grafts manufactured in Germany, Japan, and Ireland. Third, Open Payments reporting under the Physician Payments Sunshine Act, administered by CMS, requires manufacturers to disclose physician payments, adding compliance cost and audit exposure under the Anti-Kickback Statute.

Policy-Created Opportunities in U.S. Vascular Grafts

The CMS CY2026 Outpatient Prospective Payment System final rule began phasing out the Inpatient Only list, opening peripheral bypass and selected endovascular procedures to ambulatory surgical centers and hospital outpatient departments. Graft suppliers offering compact, pre-packaged ePTFE kits gain volume as site-of-service shifts away from inpatient settings, where bundled DRG payments previously restricted purchasing.

Device pass-through status under Section 1833(t)(6) of the Social Security Act provides separate OPPS payment for qualifying new devices, creating a commercial route for novel endovascular graft designs. Veterans Affairs demand also expands through VA MISSION Act community care referrals, where national contract pricing via Federal Supply Schedule procurement rewards suppliers with validated clinical outcomes data.

Market at a Glance

MetricValue
Market Size 2024USD 1.12 billion
Market Size 2032USD 1.78 billion
Growth Rate (CAGR)6.0%
Most Critical Decision FactorFDA PMA approval timeline and CMS reimbursement classification
Largest RegionSouth (Texas, Florida, Georgia)
Competitive StructureConsolidated; top five suppliers hold roughly 70 percent share

Leading Market Participants

  • W. L. Gore and Associates
  • Terumo Aortic
  • LeMaitre Vascular
  • BD (Bard Peripheral Vascular)
  • Medtronic
  • Cook Medical
  • Getinge
  • Artivion
  • Bolton Medical
  • JOTEC

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act of 1938, as amended by the Medical Device Amendments of 1976, which established the device classification system and premarket approval pathway. FDA's Center for Devices and Radiological Health administers compliance, including establishment registration and device listing under 21 CFR Part 807, Unique Device Identification under 21 CFR Part 801, and Medical Device Reporting under 21 CFR Part 803. Cybersecurity requirements under Section 524B, added by the Consolidated Appropriations Act 2023, apply to connected devices.

Upcoming changes include QMSR enforcement from February 2, 2026, MDUFA VI negotiations ahead of the September 2027 expiry of MDUFA V, and the Section 232 trade outcome. Compared with regional peers, the U.S. pathway moves faster than the European Union's Medical Device Regulation (Regulation (EU) 2017/745), where notified body reviews often extend certification beyond a year. Health Canada's Medical Devices Regulations (SOR/98-282) impose comparable evidence demands for implantable grafts but lack an equivalent user fee-driven review timeline.

Long-Term Policy Outlook for Vascular Grafts in the United States

MDUFA VI, negotiated during 2026 and 2027, will set the next performance goals for premarket approval submissions and will determine whether the 180-day review target tightens. CMS will continue shifting peripheral and endovascular procedures toward ambulatory surgical centers as the Inpatient Only list phases out, moving graft purchasing decisions from hospital value committees toward ambulatory and office-based buyers.

Section 232 duties, if imposed, will raise import costs for European and Japanese graft suppliers and accelerate domestic manufacturing investment, including Gore's existing production base in Flagstaff, Arizona. Dialysis access volume will expand as Kidney Care Choices participation grows, with ePTFE access grafts holding share against arteriovenous fistulas wherever vein quality limits fistula creation.

Frequently Asked Questions

The FDA's Center for Devices and Radiological Health reviews vascular grafts under the Federal Food, Drug, and Cosmetic Act. Most synthetic aortic and peripheral grafts require premarket approval, while lower-risk products clear through 510(k) notification.
The Quality Management System Regulation replaces the Quality System Regulation at 21 CFR Part 820 effective February 2, 2026. It aligns U.S. requirements with ISO 13485:2016, so manufacturers must update design controls and supplier audit procedures.
Inpatient aortic and peripheral procedures are paid through MS-DRG bundles under the CMS Inpatient Prospective Payment System. Qualifying new devices may receive NTAP add-on payments of up to 65 percent of device cost during an initial period.
The Commerce Department opened a Section 232 investigation into imported medical devices in September 2025, and the outcome remains pending. Importers of grafts manufactured in Europe and Japan face the greatest exposure to any resulting duties.
Manufacturers must assign a Unique Device Identifier under 21 CFR Part 801 and submit establishment registration and device listings under 21 CFR Part 807. Adverse events must be reported through Medical Device Reporting under 21 CFR Part 803.

Market Segmentation

By Product Type
  • Expanded PTFE Grafts
  • Polyester (Dacron) Grafts
  • Biological and Tissue Grafts
  • Endovascular Stent Grafts
  • Hybrid Grafts
By Application
  • Aortic Repair
  • Peripheral Bypass
  • Hemodialysis Access
  • Cerebrovascular Repair
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Dialysis Clinics
  • Veterans Affairs Medical Centers

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Vascular Grafts - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Expanded PTFE Grafts
4.2 Polyester (Dacron) Grafts
4.3 Biological and Tissue Grafts
4.4 Endovascular Stent Grafts
4.5 Others
Chapter 05 Application Insights
5.1 Aortic Repair
5.2 Peripheral Bypass
5.3 Hemodialysis Access
5.4 Cerebrovascular Repair
5.5 Others
Chapter 06 End User Insights
6.1 Hospitals
6.2 Ambulatory Surgical Centers
6.3 Dialysis Clinics
6.4 Veterans Affairs Medical Centers
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 W. L. Gore and Associates
7.2.2 Terumo Aortic
7.2.3 LeMaitre Vascular
7.2.4 BD (Bard Peripheral Vascular)
7.2.5 Medtronic
7.2.6 Cook Medical
7.2.7 Getinge
7.2.8 Artivion
7.2.9 Bolton Medical
7.2.10 JOTEC
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.